Search

A study conducted at Jiangnan University in Jiangsu, China, has developed a new pH-responsive injectable hydrogel for wound healing. The hydrogel, made from tetrakis (hydroxymethyl) phosphonium sulfate (THPS), carboxymethyl chitosan (CMCS), and epsilon-poly-L-lysine (EPL), exhibits rapid gelation and antibacterial properties. The hydrogel also incorporates a Cu-metformin complex (CuMet) for sustained drug release and has exceptional water absorbency and hemostatic qualities. In vitro assessments have shown that the hydrogel accelerates wound healing by reducing bacterial colonization and inflammatory responses. This research provides insights into the potential of the developed hydrogel as a sustained-release injectable wound dressing. [Extracted from the article]

A study conducted at Mansoura University in Egypt explored alternative therapies for diabetic nephropathy (DN), a serious complication of type 2 diabetes. The researchers investigated the potential benefits of alpha-lipoic acid (alpha-LA) and metformin in ameliorating DN. The study found that the administration of metformin and alpha-lipoic acid successfully attenuated DN, improving glycemic control, kidney function, and lipid profile, while also restoring redox balance. The researchers concluded that this combination therapy could protect against DN. [Extracted from the article]

A recent study conducted by the Medical University of Silesia in Katowice, Poland, explored the relationship between vitamin D status and the impact of metformin on the hypothalamic-pituitary-thyroid axis in women with subclinical hypothyroidism. The study included three groups of women with similar characteristics, and all subjects were treated with metformin due to concomitant type 2 diabetes or prediabetes. The results showed that metformin reduced glucose, insulin resistance, and glycated hemoglobin levels in all groups, but these effects were less pronounced in women with vitamin D deficiency/insufficiency. The study concluded that low vitamin D status in young women mitigates the impact of metformin on thyrotroph secretory function. [Extracted from the article]

A recent study conducted by McGill University examined the effects of metformin, a commonly prescribed antidiabetic medication, on earthworms. The study found that earthworms exposed to high concentrations of metformin experienced weight gain and changes in their metabolite profile, including reductions in glucose and fatty acid synthesis. These findings suggest that metformin may have similar effects on earthworms as it does on humans. The study highlights the need for further research on the environmental impact of pharmaceuticals. [Extracted from the article]

A recent study conducted by researchers at Universita degli Studi di Milano explores the potential use of the antidiabetic drug metformin in the treatment of neurodegenerative diseases. Metformin has shown promise in protecting against cardiovascular and neurodegenerative diseases, as well as promoting longevity. The study focuses on the role of lysosomal-dependent processes and targets in metformin's action, highlighting the importance of lysosomal dysfunctions in neurodegenerative diseases. While metformin holds potential, further research is needed to address important issues such as dosing. This information is available in the International Journal of Molecular Sciences. [Extracted from the article]

A recent report from Stanford University Medical Center discusses the findings of a study on the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and metformin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (diabetic MASLD). The study aimed to evaluate the long-term effects of these medications on liver and non-liver complications. The results showed that SGLT-2i users had a significantly lower risk of liver complications, cardiovascular disease, chronic kidney disease, and non-liver cancer compared to users of other glucose-lowering drugs. The risk was further reduced when SGLT-2i was used in combination with metformin. This research provides valuable insights into potential pharmacological therapies for patients with type 2 diabetes and diabetic MASLD. [Extracted from the article]

A study conducted by researchers at Southern Methodist University examined the potential benefits of metformin, an antidiabetic medication, in mitigating the association between depression and inflammation. The study analyzed data from two large samples of middle-aged and older adults, primarily White and older Latino adults. The results showed that metformin usage buffered the association between depressive symptoms and inflammatory markers in the primarily White sample, but not in the older Mexican American sample. The findings suggest a potential benefit of metformin and raise questions about health equity. [Extracted from the article]

A study conducted at Memorial University of Newfoundland in St. John, Canada, introduces a new approach to transport modeling by integrating experimentally derived causal priors into neural networks. The study focuses on metformin, a pharmaceutical emerging pollutant, and its transport behavior in sandy media. The researchers used a physics-based model and data augmentation to estimate unobservable parameters and constructed a causal graph to identify impactful variables. The study demonstrates the balanced approach between expert knowledge and data-driven methods, providing enhanced interpretability in environmental modeling. [Extracted from the article]

A study conducted at King Abdulaziz University in Jeddah, Saudi Arabia, explored the relationship between miR-199b-5p expression and subclinical cardiovascular disease (CVD) in individuals with well-controlled type 1 diabetes (T1DM). The researchers found that miR-199b-5p was significantly upregulated in T1DM and correlated with vascular endothelial growth factor-D and c-reactive protein. Metformin therapy was shown to downregulate miR-199b-5p, confirming its cardio-protective effect. The study suggests that miR-199b-5p could serve as a biomarker for subclinical CVD and that metformin may be beneficial in reducing its expression. [Extracted from the article]

A recent study conducted at Delhi Technological University in India focused on the development of a hydrogel for the controlled release of Metformin Hydrochloride (Metformin HCl), a commonly used drug for type 2 diabetes. The hydrogel was synthesized using sodium alginate, CMTKG, and PSA, and was found to exhibit pH-responsive drug release, with higher release at pH 7.4 compared to pH 1.2. The hydrogel also demonstrated anti-diabetic activity and the potential to improve patient compliance and reduce side effects. The study concluded that the hydrogel possessed a porous, interconnected network structure. [Extracted from the article]

A recent study conducted by researchers at the University of Veterinary and Animal Sciences has provided new insights into antidiabetic agents, specifically focusing on metformin hydrochloride. The study explored the use of microencapsulation techniques to optimize the bioavailability and reduce gastrointestinal disturbances associated with metformin therapy. The researchers used sodium alginate as the coating material and achieved an encapsulation efficiency of up to 84%. The study concluded that the complex coacervation technique using sodium alginate was a viable method for microencapsulation of metformin hydrochloride. For more information, the full article can be accessed through the Journal of Contemporary Pharmacy. [Extracted from the article]

A recent study conducted by researchers from Shanxi Medical University in China investigated the protective effects of the antidiabetic agent metformin against preeclampsia (PE) induced by Nco-Nitro-L-arginine methyl ester (L-NAME). The study found that metformin improved pregnancy outcomes and mitigated placental histopathological deterioration in rat models of PE. Metformin also suppressed the elevation of antiangiogenic factors and stimulated the production of pro-angiogenic factors. Additionally, metformin inhibited the activation of the NLRP3 inflammasome and the excessive inflammatory response induced by L-NAME. The research suggests that metformin may have a protective effect against PE through its regulation of inflammatory response and angiogenic factors. [Extracted from the article]

A recent study conducted by researchers from Janssen Research & Development LLC examined the effect of erdafitinib, an oral pan-FGFR inhibitor, on the pharmacokinetics of midazolam and metformin in patients with advanced solid tumors harboring FGFR gene alterations. The study found that repeated dosing of erdafitinib did not have a clinically meaningful effect on the pharmacokinetics of midazolam or metformin. The research was supported by Janssen Research & Development, LLC and has been peer-reviewed. [Extracted from the article]

A recent study conducted by researchers at Chiang Mai University in Thailand explored the effects of doxorubicin, a chemotherapy drug, on alveolar bone homeostasis. The study also investigated the potential benefits of melatonin and metformin in mitigating the toxic effects of doxorubicin on the alveolar bone. The researchers found that doxorubicin treatment resulted in increased oxidative stress, inflammation, bone reabsorption, and impaired microarchitecture and periodontal condition of the alveolar bone. However, cotreatment with melatonin or metformin showed some improvement in these parameters, with melatonin being more effective in reducing oxidative stress, bone resorption, and improving microarchitecture and periodontal condition. These findings suggest that antioxidants, particularly melatonin, may have the potential to alleviate doxorubicin-induced alveolar bone toxicity. [Extracted from the article]

This document provides information about a clinical trial study on the use of metformin for individuals with prediabetes. The study aims to evaluate the effects of metformin compared to a placebo on participants with prediabetes. The study will involve oral ingestion of metformin or a placebo for 12 weeks. The recruitment for the study has not yet started, and the estimated completion date is August 1, 2026. The study is open to individuals of all genders between the ages of 18 and 55. The contact information for the primary investigator is provided. [Extracted from the article]

A recent study conducted at the Medical University of Silesia in Poland explored the impact of metformin on plasma prolactin concentration in men with drug-induced hyperprolactinemia. The study found that metformin reduced the concentration of prolactin only in men without autoimmune thyroiditis, and this reduction was correlated with improvements in insulin sensitivity and systemic inflammation. The study concluded that autoimmune thyroiditis mitigates the effect of metformin on prolactin secretion in men. Further research is needed to fully understand the relationship between metformin, autoimmune thyroiditis, and prolactin levels. [Extracted from the article]

A new report published by investigators at GlaxoSmithKline plc discusses the use of the antidiabetic agent fostemsavir in combination with other antiretrovirals for the treatment of HIV-1 infection. The report focuses on the potential drug-drug interactions between fostemsavir and metformin, a commonly used antidiabetic medication. The researchers used a physiologically based pharmacokinetic model to assess the risk of interaction and concluded that no dose adjustment is recommended for metformin when co-administered with fostemsavir. This research provides valuable information for healthcare professionals and patients who may be considering this combination therapy. [Extracted from the article]

A report from Anhui Medical University in China discusses the use of metformin, an oral antidiabetic agent, in the treatment of intervertebral disc degeneration (IVDD). Metformin has been widely used to treat type 2 diabetes mellitus (T2DM), and it has also shown potential in addressing other conditions such as obesity, cancer, and bone deterioration that are associated with T2DM. The study suggests that metformin can delay the progression of IVDD by stimulating AMP-activated kinase, enhancing autophagy, and suppressing cell senescence, apoptosis, and inflammation. The research provides insights into the mechanisms of metformin and its potential as an adjuvant therapy for IVDD. [Extracted from the article]

A recent report discusses research conducted at Gujarat University in India on the development of a composite material for improved delivery of the antidiabetic drug metformin. The researchers aimed to address the issue of premature drug release in the acidic environment of the gastrointestinal tract, which reduces the drug's effectiveness and can cause side effects. The composite, made from polymers such as guar gum, chitosan, and poly(vinyl alcohol), demonstrated good retention of metformin in simulated gastric fluid. The study suggests that this pH-sensitive composite could be a potential carrier for drugs that experience premature release in the stomach. [Extracted from the article]

A recent study conducted by researchers at Gujarat Technological University in India has developed a stability-indicating RP-HPLC method for the simultaneous determination of Metformin hydrochloride (MET) and Remogliflozin etabonate (REM) in bulk and marketed formulations. The method utilized a mobile phase of Phosphate Buffer (pH 4.0): Acetonitrile (60:40%v/v) and detected drug peaks using a UV detector at 226nm. The study found that the proposed method was specific and suitable for routine quality control analysis. This research provides valuable insights into antidiabetic agents and their analysis. [Extracted from the article]

A recent study conducted by researchers from Merck Healthcare KGaA in Darmstadt, Germany, has found that the GelShieldR sustained-release formulation tablet of GlucophageR, a brand of metformin hydrochloride, is bioequivalent to the historic version marketed in 2000. The study evaluated the bioequivalence between the current round tablet from Europe and the historic oblong tablet from the United States. The results showed that there was bioequivalence between the two formulations in terms of pharmacokinetic parameters. The researchers concluded that the efficacy and safety of GlucophageR XR can be claimed along the evolution of the formulation. [Extracted from the article]

Researchers at the University of Karachi in Pakistan have developed a new method for the simultaneous analysis of Sitagliptin and Metformin HCl in pharmaceutical formulations. The method uses reverse phase elution and a specific mobile phase composition. The study found that the method was effective in determining the combined dosage forms in pharmaceutical formulations. The research has been peer-reviewed and published in the Pakistan Journal of Pharmaceutical Sciences. [Extracted from the article]

A recent study conducted by the Research Center for Oceanography has found evidence of the antidiabetic drug metformin in the waters of Jakarta, Indonesia. Metformin is a commonly prescribed medication for diabetes, and its presence in aquatic environments has raised concerns about its impact on wildlife and human health. The study collected samples from the Angke river in Jakarta and detected metformin at three sites in concentrations ranging from 27 ng/L to 414 ng/L. This is the first report of metformin contamination in Jakarta waters, highlighting the potential increase in pharmaceutical pollution and its potential effects on the food chain and human health. [Extracted from the article]

A report from the University of Novi Sad in Serbia discusses the potential use of non-oncological drugs as adjuvant therapy for cancer treatment. The study evaluated the effects of combinations of non-toxic drugs, including disulfiram, metformin, and deoxycholic acid, on fibrosarcoma growth and tumor markers in hamsters. The results showed that these drug combinations had significant antitumor effects and could inhibit certain signaling pathways involved in cancer growth. The researchers suggest that these combinations have the potential to be used as effective and non-toxic adjuvant therapy in oncology. [Extracted from the article]

A study conducted at the University of Sciences and Technology Houari Boumediene in Algiers, Algeria, aimed to improve the administration of metformin, an antidiabetic agent, through the creation of solid lipid microparticles (SLMs). The researchers used a double emulsion hot homogenization technique to create the SLMs and studied the effects of surfactants and homogenization time on particle characteristics and performance. The optimized SLM formulation showed an encapsulation efficiency of 82% and a particle size of 2 μm, with sustained drug release. The study highlights the potential of metformin SLMs for improved cutaneous delivery and extended drug release. [Extracted from the article]

A recent study conducted at the University of Groningen in the Netherlands focused on lactic acidosis, a condition associated with the use of the drug metformin in type 2 diabetes. The study used stable-isotope labeled GC-MS methods to measure amino acids and metabolites in plasma, urine, and dialysate samples from a patient with metformin-associated lactic acidosis. The results showed lower concentrations of amino acids in plasma, normal concentrations of nitric oxide metabolites, and normal concentrations of malondialdehyde, an oxidative stress biomarker. The study suggests that GC-MS is a versatile analytical tool for measuring different substances in complex biological samples in clinical settings. [Extracted from the article]

A recent study conducted by researchers at the Victor Babes National Institute for Pathology and Biomedical Sciences has found that metformin, a commonly used antidiabetic drug, can generate high levels of N-nitrosodimethylamine (NDMA) when exposed to simulated gastric conditions with high nitrite concentrations. NDMA is a known carcinogen and has been detected in various finished drug products, leading to recalls in the USA and Europe. The study suggests that patients taking metformin may be exposed to NDMA when high nitrite levels are present in their stomach, and the researchers recommend including this information in patient package inserts. [Extracted from the article]

A recent study conducted by researchers at Poznan University of Medical Sciences in Poland explored the effectiveness of metformin therapy as a treatment for acne vulgaris. The researchers found that metformin, an antihyperglycemic agent, showed significant improvement in the skin condition of acne patients. The study suggests that metformin may be a potential therapy option for acne, particularly for patients without endocrinopathies. The research highlights the importance of diagnosing and treating underlying causes of acne, such as metabolic and hormonal disorders, to improve the effectiveness of acne treatment. [Extracted from the article]

A recent study conducted by researchers at Texas Tech University Health Sciences Center has found that metformin, an antidiabetic medication, may have potential therapeutic benefits in the treatment of glioblastoma (GBM), the most common primary malignant brain tumor. The study investigated the effects of metformin on GBM cell viability and its immunomodulatory effects on GBM cells. The researchers observed that metformin treatment had a dose-response effect on GBM cell viability and also had an immunomodulatory effect on GBM cells. However, further research is needed to understand how these findings would translate into successful in vivo approaches. [Extracted from the article]

A study conducted at Sardar Patel University in Gujarat, India, has explored the use of biopolymer-based hydrogels for the removal of pollutants from water. The researchers focused on the adsorption of two drugs, sodium Metformin hydrochloride (MF) and sodium diclofenac (SD), using a batch adsorption process. The results showed that SD had a higher adsorption affinity compared to MF, with 40 mg of adsorbent demonstrating greater efficiency for SD (89.2%) than MF (60.41%). The adsorption of both drugs followed the Langmuir adsorption isotherm and Pseudo-2nd-order kinetic model, suggesting a monolayer and chemisorption mechanism. [Extracted from the article]

A recent study examined the effect of concomitant metformin treatment on cisplatin-induced nephrotoxicity in adult head and neck cancer patients. The study included 18 patients who received metformin alongside cisplatin treatment and 54 patients who did not receive metformin. The data showed a lower incidence of nephrotoxicity in the metformin group compared to historical controls, but no statistically significant differences were found between the two cohorts. The study reaffirmed the higher risk of nephrotoxicity for patients on a three-week regimen compared to a weekly regimen. However, the sample size limitation prevented the researchers from establishing a statistically significant effect. [Extracted from the article]

A recent study conducted by researchers at Pennsylvania State University (Penn State) examined the trends in vitamin B12 level testing among patients on metformin, a commonly prescribed medication for type 2 diabetes. The study found that the use of vitamin B12 level testing has significantly declined over the years, potentially impacting the early detection of B12 deficiency. The researchers recommend further studies to understand the reasons and impact of this trend. This information is important for individuals with diabetes and healthcare providers to be aware of the potential risks associated with metformin therapy. [Extracted from the article]

A study conducted by researchers from Ardabil University of Medical Sciences investigated the effects of metformin and coenzyme Q10 on doxorubicin-induced oxidative hepatotoxicity in rats. Doxorubicin is a chemotherapy drug that can cause severe side effects such as liver damage. The study found that treatment with metformin, coenzyme Q10, or a combination of both significantly reduced liver enzyme activity, improved antioxidant parameters, and protected against liver complications caused by doxorubicin. These findings suggest that metformin and coenzyme Q10 may have potential as protective agents against chemotherapy-induced liver damage. [Extracted from the article]

A study conducted by researchers at King Saud bin Abdulaziz University for Health Sciences in Saudi Arabia compared the performance of two methods, Ultra-high performance liquid chromatography (UHPLC) and UV-Vis spectrophotometry, for quantifying metformin hydrochloride in different pharmaceutical tablet products. The study found that both methods were successful in analyzing metformin hydrochloride, with the UHPLC method showing repeatability and reproducibility of less than 1.578% and 2.718%, respectively, and the UV-Vis spectrophotometric method showing repeatability and reproducibility of less than 3.773% and 1.988%, respectively. The study concluded that these methods can be used for the quantitative analysis of metformin hydrochloride in various pharmaceutical tablet products. [Extracted from the article]

A recent study analyzed the effect of metformin treatment on the circulating proteome, aiming to understand its mechanism of action and identify potential targets for diabetes treatment. The study analyzed data from multiple cohorts and platforms, finding that 97 proteins were associated with metformin exposure, and four proteins were consistently associated across all studies and platforms. The analysis also revealed that metformin exposure had an effect on intestinal tissues. These findings provide further insight into the mechanism of action of metformin and highlight the importance of considering metformin exposure in proteomic studies and clinical care. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent report from Shanghai Jiao Tong University discusses the potential use of metformin, an antidiabetic drug, in stimulating antitumor immunity in colorectal cancer. The researchers used single-cell RNA sequencing to show that metformin can remodel the immune landscape of colorectal cancer by increasing the proportion and function of CD8+ T cells. The study also found that metformin reprograms tryptophan metabolism, restoring tryptophan availability for CD8+ T cells and increasing their cytotoxicity. This research suggests that metformin could be a potential immunotherapeutic strategy for treating colorectal cancer. [Extracted from the article]

A recent report published in the Asian Journal of Pharmaceutical Analysis describes a new method for quantifying and studying the degradation of antidiabetic agents, specifically Alogliptin, Saxagliptin, and Metformin, in pharmaceutical dosage forms. The researchers established a stability indicating RP-HPLC technique using an isocratic method and achieved separation of the drugs using specific conditions. The method was found to be precise and stable, with no interfering peaks observed. This research provides valuable insights for the development and analysis of antidiabetic medications. [Extracted from the article]

A recent study conducted by researchers at the University of Buenos Aires in Argentina explored the effects of metformin, a commonly used antidiabetic medication, on Sertoli cells and blood-testis barrier (BTB) formation. The study found that metformin decreased fatty acid oxidation and increased 3-hydroxybutyrate production in vitro. In vivo, metformin was found to mildly increase BTB permeability and induce ZO-1 redistribution, suggesting an alteration of cell junctions. However, the study concluded that metformin treatment during the juvenile period did not significantly affect testicular function in adulthood. [Extracted from the article]

A recent study conducted by researchers at Vilnius University in Lithuania explored the potential of using metformin as an adjuvant therapy for chemoresistant CD34+ acute myeloid leukemia (AML) cells. AML is the second most common type of leukemia in adults, and the survival rate for patients is low due to the development of chemoresistance. The study found that metformin, when used in combination with conventional chemotherapy or other drugs, inhibited the growth of AML cells and affected the cell cycle. The researchers believe that metformin has the potential to be used as an adjuvant in the treatment of resistant AML cells and that their findings will contribute to the development of new therapeutic strategies. [Extracted from the article]

A recent study conducted by researchers at the University of California explores the potential of using the diabetes medication metformin as a therapeutic intervention for hemorrhagic shock (HS). HS is a condition that contributes significantly to mortality rates, and new resuscitation strategies are needed. The study involved surgically preparing rats and inducing HS, then administering metformin alongside a resuscitation solution. The results showed that metformin treatment led to improved blood pressure and reduced brain injury markers, as well as alterations in metabolites related to cellular energy management. However, further research is needed to fully understand the role of these changes. This study was supported by a grant from the National Institutes of Health. [Extracted from the article]

A study conducted at Zhejiang University in Hangzhou, China, investigated the effects of combining Exenatide and Metformin on patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. The study included 128 patients who were randomly assigned to either Group A (receiving Metformin) or Group B (receiving Exenatide injection and Metformin). After 24 weeks of treatment, Group B showed lower levels of fasting blood glucose, postprandial glucose, triglycerides, total cholesterol, alanine aminotransferase, and aspartate aminotransferase compared to Group A. Additionally, Group B had lower counts of Escherichia coli and Enterococcus faecalis, and higher counts of Bifidobacteria and Lactobacillus. The researchers concluded that the combination of Exenatide and Metformin may have synergistic effects in improving metabolic and hepatic parameters, as well as regulating intestinal flora, providing a promising therapeutic option for these patients. [Extracted from the article]

Researchers at "Grigore T. Popa" University of Medicine and Pharmacy conducted a study on the effects of platelet-rich plasma (PRP) on dermal fibroblasts in the presence of metformin and rapamycin, two antidiabetic agents. The study found that a concentration of 1% PRP had the effect of transforming fibroblasts into younger cells, especially when combined with metformin and rapamycin. However, a concentration of 5% PRP had the opposite effect, causing biochemical aging of the fibroblasts. The study demonstrates the hormetic effects of PRP on cultured fibroblasts. [Extracted from the article]